Given the differences between cancer and normal cell oxidative metabolism, newly developed pentaazamacrocyclic Mn (II)-containing (MnPAM) SOD, combined with pharmacological ascorbate, enhances the radiation-mediated therapeutic efficacy in NSCLC cells [47], suggesting that cancerous SODs could be potential therapeutic targets, and the development of targeting strategies for cancerous redox-regulating enzymes should be prominent therapeutic outcomes. This evidence concerns the gene SOD1 and non-small cell lung carcinoma.